Roivant unveils new subsidiary on deal with Ligand

By Allison Johnson | Mar 7, 2018 | 11:30 PM GMT

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant